AdvanCell Closes A$18M Series B Funding Led by Morningside
Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs. SYDNEY–(BUSINESS WIRE)–#AdvanCell–AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 … [Read more…]
